We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Molecular Tests Screens for Retinal Diseases

By LabMedica International staff writers
Posted on 01 Feb 2011
A custom resequencing chip has been designed to identify known and new mutations in retinal disease genes. More...


The retinal resequencing chip covers all exons of 90 retinal disease genes and it has been tested with multiplex primer sets for 1,445 amplicons representing the genes included on the chip.

A collaborative study carried out at the Netherlands Institute for Neuroscience (Amsterdam, The Netherlands), tested their retinal DNA resequencing chip and patient pooling strategy. This enabled detection of multiple retinal disease gene sequences in numerous patients, at the same time. DNA was extracted from peripheral blood from 60 patients with a variety of retinal disorders, including Leber's congenital amaurosis, ocular albinism, pseudoxanthoma elasticum, retinitis pigmentosa, and Stargardt's disease.

The custom 300-kb resequencing chip is designed for polymerase chain reaction (PCR) amplification, DNA fragmentation, and chip hybridization performance. Hybridization signals were analyzed using appropriate detection software and this resequencing approach was validated by Sanger sequence technology. The new chip can screen up to 90 retinal disease genes in as many as 20 patients at the same time and return results faster than current tests. Since 150 genes related to 30 retinal diseases have been identified, and on average, at least five genes must be considered for each type of disease.

Arthur A.B. Bergen, PhD, the lead author of the study, said, "In initial and replicated tests, we achieved a high 99% detection rates, 100% reproducibility of results and no false-positives. Unlike current methods, our chip can detect both known and new genetic sequence changes associated with retinal disorders, an advance that will further our understanding of disease mechanisms as well as improving diagnosis and treatment. The chip is fully validated for DNA diagnostic purposes, and an upgraded version will be available in early 2011 at the Netherlands Institute for Neuroscience, Amsterdam. The study was published in January 2011, in the journal Ophthalmology.

Related Links:
Netherlands Institute for Neuroscience



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Repetitive Pipette
VWR® Stepper Pro
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.